SGLT2 inhibitors block sodium-glucose cotransporter 2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion independent of insulin secretion. This mechanism activates metabolic stress-response pathways including AMPK signaling and mitochondrial biogenesis while reducing systemic hyperglycemia and hyperinsulinemia, thereby modulating nutrient-sensing and metabolic aging pathways central to longevity regulation. In human trials, SGLT2 inhibitors demonstrate reduced cardiovascular mortality, slower CKD progression, and lower heart failure hospitalization rates across glycemic and non-glycemic populations; preclinical models show extended healthspan markers including improved mitochondrial function, reduced oxidative stress, and enhanced autophagy. These pleiotropic effects suggest potential broad-spectrum aging deceleration beyond glucose control, though direct human lifespan data remain limited to observational follow-up periods.
SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) are FDA-approved for type 2 diabetes, heart failure, and chronic kidney disease. Their broader healthspan implications are tracked separately from these core approved indications.
The EMPA-REG OUTCOME trial (2015) reported a hazard ratio of 0.62 for cardiovascular death, a key landmark result underlying this intervention's Strong evidence tier on Geroevidence.
Current pooled data is drawn primarily from diabetic and heart-failure populations. Evidence specific to non-diabetic, longevity-context use is more limited — see the full profile for the current literature breakdown.
Genital mycotic infections and, rarely, diabetic ketoacidosis (including euglycemic DKA) have been reported in approved indications. Volume depletion is also a noted risk, particularly in older adults.
Both are graded Strong. SGLT2 inhibitors show HR 0.62 for cardiovascular death (EMPA-REG 2015); GLP-1 agonists show HR 0.80 for MACE (SELECT 2023). See the GLP-1 agonists profile for direct comparison.